Zacks Investment Research upgraded shares of SIMCERE PHARMAC (SCR) from NEUTRAL to OUTPERFORM on March 11, 2013, with a target price of $9.00.
SIMCERE PHARMACEUTICAL GROUP is a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing China market. Their strategic focus is to introduce first to market generic and innovative pharmaceuticals for the treatment of diseases with high incidence and or mortality rate and for which there is a clear demand for more effective pharmacotherapy.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SIMCERE PHARMAC (SCR),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment